Bromocriptine mesylate

• CAT Number: I002704
• CAS Number: 22260-51-1
• Molecular Formula: C32H40BrN5O5 • CH3SO3H
• Molecular Weight: 750.70
• Purity: ≥95%
• Synonyms: (6aR,9R)-5-bromo-N-((2R,5S,10aS,10bS)-10b-hydroxy-5-isobutyl-2-isopropyl-3,6-dioxooctahydro-2H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide methanesulfonate
• Target: Dopamine Receptor
• Solubility: DMSO: ≥ 30 mg/mL
• Storage: Store at RT
• IUPAC Name: (6aR,9R)-5-bromo-N-[(1S,2S,4R,7S)-2-hydroxy-7-(2-methylpropyl)-5,8-dioxo-4-propan-2-yl-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide;methanesulfonic acid
• InChI: InChI=1S/C32H40BrN5O5.CH4O3S/c1-16(2)12-24-29(40)37-11-7-10-25(37)32(42)38(24)30(41)31(43-32,17(3)4)35-28(39)18-13-20-19-8-6-9-22-26(19)21(27(33)34-22)14-23(20)36(5)15-18;1-5(2,3)4/h6,8-9,13,16-18,23-25,34,42H,7,10-12,14-15H2,1-5H3,(H,35,39);1H3,(H,2,3,4)/t18-,23-,24+,25+,31-,32+;/m1./s1
• InChIKey: NOJMTMIRQRDZMT-GSPXQYRGSA-N
• SMILES: CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CN(C5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O.CS(=O)(=O)O

Bromocriptine mesylate (Cat No.: I002704) is a dopamine D2 receptor agonist used to treat conditions related to dopamine dysfunction, such as Parkinson’s disease, hyperprolactinemia, and type 2 diabetes. By stimulating dopamine receptors, it helps regulate motor control, suppress prolactin secretion, and improve insulin sensitivity. It also has applications in managing acromegaly and menstrual disorders. Bromocriptine’s ability to modulate neuroendocrine and metabolic pathways makes it a versatile therapeutic agent with both neurological and endocrine benefits in clinical and research settings.

Overview of Clinical Research

Bromocriptine mesylate is a dopamine D2 receptor agonist. It is marketed to treat Type 2 diabetes mellitus.

Reference

1. Gardner B, et al. Agonist action at D2(long) dopamine receptors: ligand binding and functional assays. Br J Pharmacol. 1998 Jul;124(5):978-84.
2. Renodon A, et al. Bromocriptine is a strong inhibitor of brain nitric oxide synthase: possible consequences for the origin of its therapeutic effects.FEBS Lett. 1997 Apr 7;406(1-2):33-6.
3. Wynalda MA, et al. Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen. Drug Metab Dispos. 1997 Oct;25(10):1211-4.
4. Rana DG, et al. Dopamine mediated antidepressant effect of Mucuna pruriens seeds in various experimental models of depression. Ayu. 2014 Jan;35(1):90-7.
5. Dieb W, et al. Nigrostriatal dopaminergic depletion increases static orofacial allodynia. J Headache Pain. 2016;17:11.